The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
04/25/2023
ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities
2022 Annual Results
01/12/2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248.
12/29/2022
ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao
12/01/2022
Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products
10/25/2022
ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates
10/06/2022
ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis
Investors Webinar of Sept 20th, 2022
09/15/2022
ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th
09/07/2022
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes
2022 AdoShell Islets Presentation
06/21/2022
ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes
05/18/2022
ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao
05/09/2022
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao
04/11/2022
ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao
03/28/2022
Adocia strengthens its cash position by 19 million euros following a real estate transaction
10/14/2021
ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China
Join our mailing list. Subscribe